Cargando…

Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis

INTRODUCTION: In patients with inadequate response or intolerance to first biologic disease-modifying antirheumatic drug (bDMARD), guidelines recommend switching to an agent of different mechanism of action or to another bDMARD. However, the reasons behind switching between bDMARD/targeted synthetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holdsworth, Elizabeth A., Donaghy, Bethany, Fox, Kathleen M., Desai, Pooja, Collier, David H., Furst, Daniel E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572299/ https://www.ncbi.nlm.nih.gov/pubmed/34487340 http://dx.doi.org/10.1007/s40744-021-00357-1

Ejemplares similares

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
por: Rigby, William F. C., et al.
Publicado: (2017)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™
por: Zhao, Hongru, et al.
Publicado: (2023)

Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme
por: Hirata, Koichi, et al.
Publicado: (2020)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs
por: Kalweit, Maria, et al.
Publicado: (2023)

Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
por: Ueda, Kaname, et al.
Publicado: (2019)

Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
por: Lukas, Cédric, et al.
Publicado: (2019)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
por: Boyadzhieva, Vladimira, et al.
Publicado: (2018)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
por: Nozaki, Yuji
Publicado: (2021)

Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry
por: Lin, Ching-Tsai, et al.
Publicado: (2021)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
por: Cappelli, Laura C., et al.
Publicado: (2023)

Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
por: Jung, Ju-Yang, et al.
Publicado: (2023)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study
por: An, Yuan, et al.
Publicado: (2016)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?
por: Romão, Vasco Crispim, et al.
Publicado: (2013)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
por: Ferrufino, Cheryl P, et al.
Publicado: (2018)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
por: Strangfeld, A, et al.
Publicado: (2017)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
por: Liang, Huifang, et al.
Publicado: (2019)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
por: Triaille, Clement, et al.
Publicado: (2021)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
por: Marasco, Emiliano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7tvv02p4l14ugcfjmd28qq41tl